Daily Journal masthead

French drug maker Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes

bug
Share/Save/Bookmark

PARIS — French drug maker Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes.

Sanofi made 4.29 billion euros ($4.8 billion) last year, compared to 4.39 billion in 2014. In a statement, Sanofi said it "made meaningful progress with key launches, multiple business development activities and our efforts to simplify the organization."

In December Sanofi and German pharmaceutical company Boehringer Ingelheim said they are pursuing an asset swap that would see the German firm take over Sanofi's Merial animal health unit, which is valued at 11.4 billion euros. Sanofi is to acquire a large part of Boehringer's consumer health care business.

Think your friends should see this? Share it with them!

Story copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Feedback, Corrections and Other Requests: AP welcomes feedback and comments from readers. Send an email to info@ap.org and it will be forwarded to the appropriate editor or reporter.


We also have more stories about:
(click the phrases to see a list)

Category:

Follow Daily Journal:

All content copyright ©2016 Daily Journal, a publication of AIM Media Indiana unless otherwise noted.
All rights reserved. Privacy policy.